Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 ...Middle East

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective...

Hence then, the article about theravance biopharma inc announces top line results from phase 2 study of nezulcitinib in patients hospitalized with acute lung injury due to covid 19 was published today ( Monday 21/06/2021 - 01:31 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 )

Also on site :

• Marler Clark Urges Parents to Stop Using Nara Organics Whole Milk Organic Powdered Infant Formula Amid Multistate Infant Botulism Outbreak -- Product Sold Nationwide at Target
• La generación Z es más renuente al riesgo. Los expertos dicen que eso perjudica sus relaciones amorosas
• Babcock & Wilcox Deadline: BW Investors Have Opportunity to Lead Babcock & Wilcox Enterprises, Inc. Securities Fraud Lawsuit